These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35507433)

  • 1. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Clin Nucl Med; 2022 Jun; 47(6):503-511. PubMed ID: 35507433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polish experience in Peptide receptor radionuclide therapy.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
    Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals.
    Wallner PE; Yoo DC; Calais J; Escorcia FE; Mari Aparici C; Michalski J; Morris M; Morris ZS; Pryma D; Rabatic BM; Sharma N; Vapiwala N; Ghesani MV; Subramaniam RM; Small W; Schechter NR
    Am J Clin Oncol; 2024 Apr; 47(4):169-176. PubMed ID: 38131352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lutetium oxodotreotide (
    Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
    BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M
    Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
    Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
    Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Das S; Al-Toubah T; El-Haddad G; Strosberg J
    Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1023-1031. PubMed ID: 31652074
    [No Abstract]   [Full Text] [Related]  

  • 13. Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (
    Satapathy S; Bhattacharya A; Sood A; Kapoor R; Gupta R; Sood A; Sharma P; Khosla D; Mittal BR
    Cancer Biother Radiopharm; 2022 Feb; 37(1):23-29. PubMed ID: 34185573
    [No Abstract]   [Full Text] [Related]  

  • 14. ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies.
    Hong K; Akinwande O; Bodei L; Chamarthy MR; Devlin PM; Elman S; Ganguli S; Kennedy AS; Koo SJ; Ouhib Z; Padia SA; Salem R; Selwyn RG; Yashar CM; Yoo DC; Zaki BI; Hartford AC; Trimmer CK
    Brachytherapy; 2021; 20(3):497-511. PubMed ID: 33824051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
    Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
    Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Lutetium [
    Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
    J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of
    Zhang J; Song Q; Cai L; Xie Y; Chen Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radionuclide Therapy for Neuroendocrine Tumors.
    Cives M; Strosberg J
    Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.